Aclaris Therapeutics (ACRS) Competitors

$4.54 +0.01 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$4.54 +0.00 (+0.11%)

As of 04:36 PM Eastern

ACRS vs. GPCR, ARQT, IRON, VERA, and NBTX

Should you buy Aclaris Therapeutics stock or one of its competitors? MarketBeat compares Aclaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclaris Therapeutics include Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Disc Medicine (IRON), Vera Therapeutics (VERA), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.

How does Aclaris Therapeutics compare to Structure Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 0.79 beat Aclaris Therapeutics' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its share price is 231% less volatile than the broader market.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aclaris Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	80.98	-$64.92M	-$0.56	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Structure Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Structure Therapeutics' return on equity of -24.91% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Structure Therapeutics	N/A	-24.91%	-23.67%

Aclaris Therapeutics currently has a consensus price target of $11.29, indicating a potential upside of 148.58%. Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 181.64%. Given Structure Therapeutics' higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Aclaris Therapeutics and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Arcutis Biotherapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Aclaris Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	6.99	-$16.14M	-$0.03	N/A
Aclaris Therapeutics	$7.83M	80.98	-$64.92M	-$0.56	N/A

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.00 equaled Aclaris Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 61.83%. Aclaris Therapeutics has a consensus price target of $11.29, suggesting a potential upside of 148.58%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

98.3% of Aclaris Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Arcutis Biotherapeutics has a net margin of -0.57% compared to Aclaris Therapeutics' net margin of -832.58%. Arcutis Biotherapeutics' return on equity of -1.41% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Summary

Arcutis Biotherapeutics beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Disc Medicine?

Aclaris Therapeutics (NASDAQ:ACRS) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

In the previous week, Disc Medicine had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Disc Medicine and 2 mentions for Aclaris Therapeutics. Disc Medicine's average media sentiment score of 0.89 beat Aclaris Therapeutics' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Disc Medicine	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics presently has a consensus price target of $11.29, indicating a potential upside of 148.58%. Disc Medicine has a consensus price target of $105.30, indicating a potential upside of 56.86%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 5.6% of Aclaris Therapeutics shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aclaris Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	80.98	-$64.92M	-$0.56	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Disc Medicine has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Disc Medicine's return on equity of -36.94% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Aclaris Therapeutics beats Disc Medicine on 9 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Vera Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Aclaris Therapeutics has higher revenue and earnings than Vera Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	80.98	-$64.92M	-$0.56	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Vera Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Vera Therapeutics	N/A	-74.86%	-60.18%

Aclaris Therapeutics currently has a consensus price target of $11.29, suggesting a potential upside of 148.58%. Vera Therapeutics has a consensus price target of $79.00, suggesting a potential upside of 129.99%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 2 articles in the media. Vera Therapeutics' average media sentiment score of 0.29 beat Aclaris Therapeutics' score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 5.6% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aclaris Therapeutics beats Vera Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Nanobiotix presently has a consensus price target of $26.67, suggesting a potential downside of 33.63%. Aclaris Therapeutics has a consensus price target of $11.29, suggesting a potential upside of 148.58%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nanobiotix has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Aclaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	52.88	-$27.11M	N/A	N/A
Aclaris Therapeutics	$7.83M	80.98	-$64.92M	-$0.56	N/A

Nanobiotix has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Nanobiotix's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

In the previous week, Nanobiotix had 11 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 13 mentions for Nanobiotix and 2 mentions for Aclaris Therapeutics. Nanobiotix's average media sentiment score of 0.25 beat Aclaris Therapeutics' score of 0.00 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nanobiotix and Aclaris Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$634.06M	$3.02B	$6.34B	$12.28B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	-8.11	17.79	20.92	25.48
Price / Sales	80.98	253.34	521.15	73.33
Price / Cash	N/A	56.99	43.18	55.00
Price / Book	4.41	4.58	9.98	7.01
Net Income	-$64.92M	$74.99M	$3.55B	$335.16M
7 Day Performance	-5.42%	-2.46%	0.40%	-0.30%
1 Month Performance	8.87%	-4.23%	-0.04%	1.14%
1 Year Performance	251.94%	36.32%	34.95%	34.69%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	2.2245 of 5 stars	$4.54 +0.2%	$11.29 +148.6%	+235.6%	$634.06M	$7.83M	N/A	100
GPCR Structure Therapeutics	3.1731 of 5 stars	$38.32 -2.0%	$109.25 +185.1%	+49.5%	$2.71B	N/A	N/A	136
ARQT Arcutis Biotherapeutics	2.8386 of 5 stars	$21.24 +0.3%	$34.00 +60.1%	+41.1%	$2.66B	$415.62M	N/A	150	High Trading Volume
IRON Disc Medicine	2.3325 of 5 stars	$69.23 +1.4%	$104.80 +51.4%	+33.8%	$2.64B	N/A	N/A	30
VERA Vera Therapeutics	3.1642 of 5 stars	$36.63 +1.2%	$79.60 +117.3%	+63.0%	$2.61B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. GPCR, ARQT, IRON, VERA, and NBTX

How does Aclaris Therapeutics compare to Structure Therapeutics?

Summary

How does Aclaris Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Aclaris Therapeutics compare to Disc Medicine?

Summary

How does Aclaris Therapeutics compare to Vera Therapeutics?

Summary

How does Aclaris Therapeutics compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. GPCR, ARQT, IRON, VERA, and NBTX

How does Aclaris Therapeutics compare to Structure Therapeutics?

Does the media refer more to ACRS or GPCR?

Which has more volatility & risk, ACRS or GPCR?

Do insiders and institutionals believe in ACRS or GPCR?

Which has stronger valuation & earnings, ACRS or GPCR?

Is ACRS or GPCR more profitable?

Do analysts rate ACRS or GPCR?

Summary

How does Aclaris Therapeutics compare to Arcutis Biotherapeutics?

Which has more volatility and risk, ARQT or ACRS?

Which has higher valuation & earnings, ARQT or ACRS?

Does the media refer more to ARQT or ACRS?

Do analysts rate ARQT or ACRS?

Do insiders & institutionals have more ownership in ARQT or ACRS?

Is ARQT or ACRS more profitable?

Summary

How does Aclaris Therapeutics compare to Disc Medicine?

Does the media prefer ACRS or IRON?

Do analysts prefer ACRS or IRON?

Do insiders & institutionals believe in ACRS or IRON?

Which has higher earnings & valuation, ACRS or IRON?

Which has more volatility & risk, ACRS or IRON?

Is ACRS or IRON more profitable?

Summary

How does Aclaris Therapeutics compare to Vera Therapeutics?

Which has more volatility and risk, ACRS or VERA?

Which has preferable earnings & valuation, ACRS or VERA?

Is ACRS or VERA more profitable?

Do analysts rate ACRS or VERA?

Does the media favor ACRS or VERA?

Do insiders and institutionals hold more shares of ACRS or VERA?

Summary

How does Aclaris Therapeutics compare to Nanobiotix?

Do analysts prefer NBTX or ACRS?

Do insiders & institutionals have more ownership in NBTX or ACRS?

Which has more volatility & risk, NBTX or ACRS?

Which has stronger earnings & valuation, NBTX or ACRS?

Is NBTX or ACRS more profitable?

Does the media refer more to NBTX or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools